Cutaneous mucormycosis in an immunocompromised patient: a case report

Suthananthan, Arul; Koek, Sharnice; Sieunarine, Kishore

doi:10.1093/jscr/rjx056

Cited by 9 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides Aspergillus and Fusarium, Rhizopus can also cause severe and fatal infections in immunocompromised patients [31,32]. The treatment of zygomycosis is problematic and frequently associated with suboptimal therapeutic outcomes [33].…”

Section: Resultsmentioning

confidence: 99%

Susceptibility of Filamentous Fungi to Voriconazole in Malaysia Tested by Sensititre YeastOne and CLSI Microdilution Methods

Tan¹,

Ginsapu²,

Amran³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Voriconazole is a trizaole antifungal to treat fungal infection. In this study, the susceptibility pattern of voriconazole against filamentous fungi was studied using Sensititre® YeastOne and Clinical & Laboratory Standards Institute (CLSI) M38 broth microdilution method. Methods: The suspected cultures of Aspergillus niger, A. flavus, A. fumigatus, A. versicolor, A. sydowii, A. calidoutus, A. creber, A. ochraceopetaliformis, A. tamarii, Fusarium solani, F. longipes, F. falciferus, F. keratoplasticum, Rhizopus oryzae, R. delemar, R. arrhizus, Mucor sp., Poitrasia circinans, Syncephalastrum racemosum and Sporothrix schenckii were received from hospitals. Their identification had been confirmed in our lab and susceptibility tests were performed using Sensititre® YeastOne and CLSI M38 broth microdilution method. The significant differences between two methods were calculated using Wilcoxon Sign Rank test.Results: Mean of the minimum inhibitory concentrations (MIC) for Aspergillus spp. and Fusarium were within 0.25 μg/mL-2.00 μg/mL by two methods except A. calidoutus, F. solani and F. keratoplasticum. Moreover, mean of MIC for S. schenkii were around 3.00 μg/mL by two methods. In contrast, mean of MIC for Rhizopus spp., Mucor sp., P. circinans and S. racemosum were ≥6.00 μg/mL by two methods. Generally, the MIC obtained by Sensititre YeastOne was one two-fold increase or decrease compared with the results obtained by CLSI method. The overall agreement between Sensititre YeastOne and CLSI methods to test susceptibility testing of voricaonazole was more than 70% except A. sydowii. The significant differences between two methods were significant when tested on A. niger, A. flavus, A. fumigatus, A. versicolor, A. sydowii, F. solani and S. schenkii. Conclusions: In conclusion, Sensititre YeastOne method appears to be an alternative procedure for antifungal susceptibility testing for some Malaysian moulds.

show abstract

Section: Resultsmentioning

confidence: 99%

Susceptibility of Filamentous Fungi to Voriconazole in Malaysia Tested by Sensititre YeastOne and CLSI Microdilution Methods

Tan¹,

Ginsapu²,

Amran³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Histopathology and culture are essential for a definitive diagnosis of mucormycosis. A multifaceted approach should be undertaken for management, including systemic antifungal treatment, prompt and aggressive surgical debridement, and reversal of underlying risks and contributing comorbidities whenever possible [5-7]. High-dose liposomal or lipid-complex amphotericin is the preferred monotherapy for mucormycosis [3, 8] and renal function should be monitored due to its nephrotoxicity.…”

Section: Discussionmentioning

confidence: 99%

“…Other treatment options that have not been well-studied include iron chelation and adjunctive cytokine therapy with interferon-γ or granulocyte-macrophage colony-stimulating factor to promote phagocytic activity [3]. Surgical debridement of localized disease is essential and enhances cure rates by preventing dissemination and managing necrosis that may not be adequately addressed by systemic antifungals [3, 7]. Prompt and aggressive surgical debridement and adjunctive antifungal therapy of localized cutaneous mucormycosis have been shown to be associated with a mortality rate of <10% [3].…”

Section: Discussionmentioning

confidence: 99%

A 39-Year-Old Male Congenital Tricuspid Atresia Patient Who Presented with a New Axillary Lesion after an Orthotopic Heart Transplant

Theodosakis

Fitzpatrick

et al. 2019

Dermatopathology

View full text Add to dashboard Cite

Mucormycosis is a rare and aggressive fungal infection, most often caused by species of the Mucor, Rhizomucor, Rhizopus, Absidia, and Cunninghamella genera. The condition most commonly affects patients with uncontrolled diabetes, HIV/AIDS, malignancy, and those receiving long-term immunosuppressive therapy. We report the case of a 39-year-old male with biopsy-proven cutaneous mucormycosis of the left axilla 4 months after an orthotopic heart transplant for congenital tricuspid atresia.

show abstract

“…It is externally developed as a painful and hardened area of the skin with swelling. Fever may also be observed in affected individuals ( Castrejón-Pérez et al, 2017 ; Suthananthan et al, 2017 ).…”

Section: Signs and Symptomsmentioning

confidence: 99%

Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread

et al. 2022

View full text Add to dashboard Cite

The havoc unleashed by COVID-19 pandemic has paved way for secondary ominous fungal infections like Mucormycosis. It is caused by a class of opportunistic pathogens from the order Mucorales. Fatality rates due to this contagious infection are extremely high. Numerous clinical manifestations result in damage to multiple organs subject to the patient’s underlying condition. Lack of a proper detection method and reliable treatment has made the management of this infection troublesome. Several reports studying the behavior pattern of Mucorales inside the host by modulation of its defense mechanisms have helped in understanding the pathogenesis of this angio-invasive infection. Many recent advances in diagnosis and treatment of this fungal infection have not been much beneficial. Therefore, there is a need to foster more viable strategies. This article summarizes current and imminent approaches that could aid effective management of these secondary infections in these times of global pandemic. It is foreseen that the development of newer antifungal drugs, antimicrobial peptides, and nanotechnology-based approaches for drug delivery would help combat this infection and curb its spread.

show abstract

Cutaneous mucormycosis in an immunocompromised patient: a case report

Cited by 9 publications

References 9 publications

Susceptibility of Filamentous Fungi to Voriconazole in Malaysia Tested by Sensititre YeastOne and CLSI Microdilution Methods

Susceptibility of Filamentous Fungi to Voriconazole in Malaysia Tested by Sensititre YeastOne and CLSI Microdilution Methods

A 39-Year-Old Male Congenital Tricuspid Atresia Patient Who Presented with a New Axillary Lesion after an Orthotopic Heart Transplant

Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread

Contact Info

Product

Resources

About

Cutaneous mucormycosis in an immunocompromised patient: a case report

Cited by 9 publications

References 9 publications

Susceptibility of Filamentous Fungi to Voriconazole in Malaysia Tested by Sensititre YeastOne and CLSI&nbsp;Microdilution Methods

Susceptibility of Filamentous Fungi to Voriconazole in Malaysia Tested by Sensititre YeastOne and CLSI&nbsp;Microdilution Methods

A 39-Year-Old Male Congenital Tricuspid Atresia Patient Who Presented with a New Axillary Lesion after an Orthotopic Heart Transplant

Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread

Contact Info

Product

Resources

About

Susceptibility of Filamentous Fungi to Voriconazole in Malaysia Tested by Sensititre YeastOne and CLSI Microdilution Methods

Susceptibility of Filamentous Fungi to Voriconazole in Malaysia Tested by Sensititre YeastOne and CLSI Microdilution Methods